BCL2L1 and B-cell chronic lymphocytic leukemia: Although navitoclax demonstrated efficacy in clinical trials for chronic lymphocytic leukemia (CLL) and small-cell lung cancer, it caused dose-limiting thrombocytopenia due to Bcl-XL’s role in platelet production [21,22].